|
WO2021064618A1
|
|
Method for treating hiv with cabotegravir and rilpivirine
|
|
GB202009684D0
|
|
Formulations
|
|
GB202009685D0
|
|
Formulations
|
|
WO2020163196A1
|
|
Method for treating hiv with dolutegravir and lamivudine
|
|
KR20200070246A
|
|
Bilayer pharmaceutical tablet formulation
|
|
WO2019030625A1
|
|
Combinations and uses and treatments thereof
|
|
US2020171039A1
|
|
Combinations and uses and treatments
|
|
US2020147092A1
|
|
Regimens for treating hiv infections and aids
|
|
US2020138845A1
|
|
Combination Drug Therapy
|
|
KR20200024259A
|
|
Combinations and uses and treatments thereof
|
|
GB201806498D0
|
|
Novel formulation
|
|
GB201806490D0
|
|
Novel formulation
|
|
GB201719410D0
|
|
Novel formulation
|
|
GB201719411D0
|
|
Novel formulation
|
|
GB201719377D0
|
|
Novel formulation
|
|
WO2018051250A1
|
|
Combination comprising tenofovir alafenamide, bictegravir and 3tc
|
|
WO2018044822A1
|
|
Combinations and uses and treatments thereof
|
|
WO2018044838A1
|
|
Combinations and uses and treatments thereof
|
|
US2019183901A1
|
|
Combinations and uses and treatments thereof
|
|
WO2018005909A1
|
|
Combinations and uses and treatments thereof
|
